Hansoh Pharmaceutical (3692) Tmuɣli n wazal
Asnulfu n AI: 3692
AI tessawal ɣef timaqsiṭ n wazal i wass n tnekkit d-iteddun, taggara n yimal akked taggara n waggʷas. Asnifel yettwamḍen seg wazal aneggaru. Aya d tinineḍ n tḥisabt, ma tga ara timsisi n usihel.
Asref n 6 isggʷasn ineggura
Premium tessaɣ-d iswiyat n tɣara n AI i wass, amalas d waggʷas n yiwen i uḍris-a akk d yisɣunan niḍen.
Serreḥ Premium🔒 Tazmilt n usenfar
Amezruy n tmuɣliyin — akk tmuɣliyin n zik akked wazal n tnekkit — d akcum n Premium.
Serreḥ PremiumƔef tneɣlaft-a
Hansoh Pharmaceutical is among the top 30 pharmaceutical companies in China. The company manufactures medicines and has 20 years of experience in research for the treatment of diseases, including cancer, diabetes, and nervous system disorders. By the end of 2020, the company had carried out more than 50 national research and development projects and obtained over 300 invention patents in China and abroad. It owns R&D centers in Shanghai, Changzhou, and Lianyungang (China), as well as in Maryland (United States).
